Basic Information


GTO ID GTC3214
Trial ID NCT05587543
Disease Nasopharyngeal Disease
Altered gene EBV
Therapeutic/Target gene Target gene
TherapyCAR-T cell|TCR-T cell
Treatment EBV CAR-T cells|EBV TCR-T cells
PhaseEarly_Phase1
Recruitment statusRecruiting
TitleClinical Study on the Safety and Efficacy of EBV CAR-T /TCR-T Cells in the Treatment of Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma
Year2022
CountryChina
Company sponsorFudan University
Other ID(s)2207257-17

Clinical Result

Cohort1: dose level 1_CAT-T
Administration route infusion
Dosage 3.0E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No
Cohort2: dose level 2_CAT-T
Administration route infusion
Dosage 9.0E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No
Cohort3: dose level 3_CAT-T
Administration route infusion
Dosage 1.5E7 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No
Cohort4: dose level 4_TCR-T
Administration route infusion
Dosage 5.0E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No
Cohort5: dose level 3_TCR-T
Administration route infusion
Dosage 1.5E7 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No
Cohort6: dose level 6_TCR-T
Administration route infusion
Dosage 3.0E7 cells/kg
Donor type autologous
Age Adult, Older_Adult
Lymph depletion No

Relationship Graph

Overview of Knowledge Graph